World Health Organization: Cancer Pain Relief with a Guide to Opioid Availability, 2nd ed. Geneva, Switzerland: WHO,. 1996.
2.
GonçalvesJA, SilvaP, AraújoP: Does tramadol have a role in pain control in palliative care?. Am J Hosp Palliat Care, 2014. [E-pub ahead of print.]
3.
McPhersonM; American Society of Health-System Pharmacists: Demystifying opioid conversion calculations: A guide for effective dosing. Bethesda, MD: American Society of Health-System Pharmacists, 2010.
4.
ScottLJ, PerryCM: Tramadol: A review of its use in perioperative pain. Drugs, 2000; 60:139–176.
5.
PrestonKL, JasinskiDR, TestaM: Abuse potential and pharmacologic comparison of tramadol and morphine. Drug Alcohol Depend, 1991; 27:7–17
6.
O'ConnorEC, MeadAN: Tramadol acts as a weak reinforce in the rat self-administration model, consistent with its low abuse liability in humans. Pharmacol Biochem Behav, 2010; 96:279–286.
7.
CiceroTJ, et al.: Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: Results of an abuse monitoring system, 1994–2004. Pharmacoepidemiol Drug Saf, 2005; 14:851–859.
MasonPJ, MorrisVA, BalcezakTJ: Serotonin syndrome: Presentation of 2 cases and review of the literature. Medicine (Baltimore), 2000; 79:201–209.
10.
FournierJ, AzoulayL, YinH, et al.: Tramadol use and the risk of hospitalization for hypoglycemia in patients with noncancer pain. JAMA Intern Med, 2015; 175:186–193.
